Beyond Target Occupancy in Triple-Negative Breast Cancer: A Medicinal Chemistry Perspective on Modality-Guided Design for Durable Network Control
- 9 June 2026
- journal article
- review article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (12) , 14020-14039
Abstract
Triple-negative breast cancer (TNBC) remains difficult to treat because durable response is rarely achieved with conventional occupancy-driven inhibition. The central challenge is not simply a lack of actionable targets but a mismatch between TNBC's adaptive network biology and the limited depth of reversible node-by-node intervention. In this Perspective, we argue that the key medicinal chemistry question is not only which protein to engage, but which chemical modality best matches a given biological liability. We focus on metabolic coupling, epigenetic scaffold dependence, immune-stromal exclusion, and DNA damage response plasticity and discuss how these vulnerabilities motivate targeted degradation, molecular glues, covalent inhibition, rational polypharmacology, or prodrug design. Across these modalities, ternary-complex productivity, linker topology, warhead presentation, isoform selectivity, exposure control, and postwashout persistence often matter more than potency alone. Biological vulnerability defines the design problem, chemical modality defines the intervention logic, and durable network control defines success.Keywords
Funding Information
- Yunnan Provincial Science and Technology Department (202502AA310002)
- Double Thousand Plan of Jiangxi Province (S2021DQKJ2195)
- Key Research and Development Program of Ningxia (2023BEG02010)
- Key Research and Development Program of Ningxia (2026ZDYF0105)
- National Natural Science Foundation of China (22267021)
- National Natural Science Foundation of China (82473762)
- Yunnan Fundamental Research Projects (202401BF070001-021)
- Yunnan Fundamental Research Projects (202501AS070025)
- Project of Innovative Research Team of Yunnan Province (202405AS350010)
- Yunnan Health Training Project of High Level Talents (L-2025002)
- Yunnan Academician Expert Workstation (202605AF350045)
This publication has 102 references indexed in Scilit:
- GPX4 Inhibitor Resistance and Metastatic Features in Triple‐Negative Breast CancerAdvanced Science, 2026
- Identification and analysis of metabolic reprogramming-related genes in triple-negative breast cancerClinical and Experimental Medicine, 2025
- A Natural LDHA Allosteric Inhibitor Geraniin Suppresses Triple‐Negative Breast Cancer Cell GrowthPhytotherapy Research, 2025
- Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple‐Negative Breast Cancer ModelsAdvanced Science, 2025
- The integrated single-cell analysis interpret the lactate metabolism-driven immune suppression in triple-negative breast cancerDiscover Oncology, 2025
- Targeted Degradation of ZBP1 with Covalent PROTACs for Anti‐Inflammatory Treatment of InfectionsAngewandte Chemie, 2025
- BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436Breast Cancer Research and Treatment, 2024
- A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancerBiochemical Pharmacology, 2022
- Metabolic changes in triple negative breast cancer-focus on aerobic glycolysisMolecular Biology Reports, 2021
- BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathwaysCellular Oncology, 2020